Shots:

• ObsEva to receive $82.81M up front & milestone including $5.69M at signing, ~$15.65M in development & commercial milestones, ~$61.47M in sales-based milestones along with royalties on commercial sales
• The agreement will use Theramex’s women’s health capabilities & commercial infrastructure to support the commercialization of linzagolix globally outside the US, Canada & Asia
• Linzagolix received the US FDA acceptance for NDA’s review to treat with an anticipated PDUFA date of Sept 13, 2022. The therapy is also being evaluated as a potential treatment for EAP while ObsEva has currently reported the results from the P-III (EDELWEISS 3) trial for the same indication

­Ref: globenewswire | Image: Clinical Trial Arena